What’s Next in Neuroscience Therapies

Posted on by admin
View

What’s Next in Neuroscience Therapies

November 19, 2019 – San Francisco

Please take note that the venue for this event has moved to the Hyatt Regency San Francisco.

Brain and neurological disorders are among the toughest conditions to diagnose and treat, but new approaches and technologies are on the horizon that could change how researchers and clinicians approach them. Join Xconomy on Tuesday, Nov. 19 for our neuroscience life science forum at the Hyatt Regency San Francisco.

Register by Nov. 15 for the Best Rate
https://xconomy.com/whats-next-neuroscience-therapies-life-science-forum/register/

B2DG Members can receive a 20% discount by using this code when you register  Bio2Device20 .

The event features scientists, entrepreneurs, and biotech executives who will discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, addiction, dementia, and Alzheimer’s. A networking reception with drinks and hors d’oeuvres follows the program.

Who should attend: biotech executives, healthcare entrepreneurs, scientific leaders, contract research organizations, and investors looking for collaboration opportunities to develop therapeutics.

Featured Speakers

  • Jane Tiller Chief Medical Officer, BlackThorn Therapeutics

Ethan Perlstein  Chief Scientific Officer, Christopher & Dana Reeve Foundation

Stephanie Yonker  Vice President of Legal, Alector

Abla Creasey Vice President of Therapeutics and Strategic Infrastructure, California Institute for Regenerative Medicine (CIRM)

Kristina Burow  Managing Director, ARCH Venture Partners

 

Agenda

3 – 4:00pm   Registration & Networking

4 – 4:30pm   Spinal Cord Injury Therapies Step Forward

Ethan Perlstein – Chief Scientific Officer, Christopher & Dana Reeve Foundation
Abla Creasey – Vice President of Therapeutics and Strategic Infrastructure, California Institute for Regenerative Medicine

Explore the cutting-edge research that could become new therapies for spinal cord injuries and other traumatic neurological damage.

4:30 – 5:00pm         AI Makes Headway Finding New Depression Drugs

Jane Tiller – Chief Medical Officer, BlackThorn Therapeutics
Kristina Burow – Managing Director, ARCH Venture Partners

Depression is a particularly challenging area for drug hunters, but BlackThorn Therapeutics says artificial intelligence, brain imaging, and other tools give it an edge finding and developing new medicines.

5 – 5:30pm   An Immunotherapy Approach to Alzheimer’s

Stephanie Yonker – Vice President of Legal, Alector

Does the immune system hold the key to understanding and treating Alzheimer’s disease? Alector is developing a drug that engages an immune cell in the brain to address neurodegeneration.

5:30 – 6:30pm         Networking Reception

Drinks & hors d’oeuvres

  • LIFE SCIENCE MEMBERS
    • Arrowhead Pharmaceuticals • Health Advances LLC
  • VENTURE MEMBERS
    • ARCH Venture Partners • SR One • Third Rock Ventures
Event Information

Event Topic:
What’s Next in Neuroscience Therapies

Event Description:

Date/Time:
Date(s) - 11/19/19
3:00 pm - 6:30 pm

Event Location:
Other:

Event Details

Event Type